Trials / Completed
CompletedNCT02783599
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaratumab | Administered IV |
| DRUG | Doxorubicin | Administered IV |
| RADIATION | External Beam Radiotherapy |
Timeline
- Start date
- 2016-10-11
- Primary completion
- 2018-07-05
- Completion
- 2018-07-05
- First posted
- 2016-05-26
- Last updated
- 2019-08-12
- Results posted
- 2019-08-12
Locations
14 sites across 5 countries: United States, France, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02783599. Inclusion in this directory is not an endorsement.